{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:54:11Z","timestamp":1790790851646,"version":"4.1.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s10067-025-07700-9","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T12:04:53Z","timestamp":1761739493000},"page":"81-91","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Long-term persistence of biological agents in the treatment of patients with rheumatoid arthritis: a systematic literature review and meta-analysis"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7671-5748","authenticated-orcid":false,"given":"Emilce Edith","family":"Schneeberger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Laura Acosta","family":"Felquer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Citera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Soriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Mysler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Masson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo Mart\u00edn","family":"Lobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"key":"7700_CR1","first-page":"250","volume-title":"Evoluci\u00f3n y Pron\u00f3stico de la Artritis Reumatoidea, Cap\u00edtulo 19","author":"G Citera","year":"2010","unstructured":"Citera G, Maldonado Cocco JA (2010) Evoluci\u00f3n y Pron\u00f3stico de la Artritis Reumatoidea, Cap\u00edtulo 19. Reumatolog\u00eda. Buenos Aires, Ediciones Azzurras, pp 250\u20133"},{"issue":"1","key":"7700_CR2","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/S0889-857X(21)00171-X","volume":"19","author":"T Pincus","year":"1993","unstructured":"Pincus T, Callahan LF (1993) What is the natural history of rheumatoid arthritis? Rheum Dis Clin North Am 19(1):128\u2013151","journal-title":"Rheum Dis Clin North Am"},{"issue":"10","key":"7700_CR3","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1002\/art.22130","volume":"54","author":"T Sokka","year":"2006","unstructured":"Sokka T, Kautiainen H, Hannonen P, Pincus T (2006) Changes in health assessment questionnaire disability scores over five years in patients with rheumatoid arthritis compared with the general population. Arthritis Rheum 54(10):3113\u20133118. https:\/\/doi.org\/10.1002\/art.22130","journal-title":"Arthritis Rheum"},{"issue":"5","key":"7700_CR4","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/RHU.0b013e3181e92d25","volume":"16","author":"EE Schneeberger","year":"2010","unstructured":"Schneeberger EE, Citera G, Maldonado Cocco JA, Salcedo M, Chiardola F, Rosemffet MG et al (2010) Factors associated with disability in patients with rheumatoid arthritis. J Clin Rheumatol 16(5):215\u2013218. https:\/\/doi.org\/10.1097\/RHU.0b013e3181e92d25","journal-title":"J Clin Rheumatol"},{"issue":"5","key":"7700_CR5","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1007\/s10067-014-2832-7","volume":"34","author":"G Citera","year":"2015","unstructured":"Citera G, Maldonado Ficco H, P\u00e9rez Alamino RS, Dal Pra F, Lencina V, Casalla L (2015) Work disability is related to the presence of arthritis and not to a specific diagnosis. Results from a large early arthritis cohort in Argentina. Clin Rheumatol 34(5):929\u201333. https:\/\/doi.org\/10.1007\/s10067-014-2832-7","journal-title":"Clin Rheumatol"},{"issue":"7S Suppl 2","key":"7700_CR6","doi-asserted-by":"publisher","first-page":"S148","DOI":"10.1097\/RHU.0000000000001196","volume":"26","author":"JE Rosa","year":"2020","unstructured":"Rosa JE, Garc\u00eda MV, Luissi A, Pierini F, Sabelli M, Mollerach F et al (2020) Rheumatoid arthritis patient\u2019s journey: delay in diagnosis and treatment. J Clin Rheumatol 26(7S Suppl 2):S148\u2013S152. https:\/\/doi.org\/10.1097\/RHU.0000000000001196","journal-title":"J Clin Rheumatol"},{"issue":"5","key":"7700_CR7","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s00296-015-3415-x","volume":"36","author":"PC Taylor","year":"2016","unstructured":"Taylor PC, Moore A, Vasilescu R, Alvir J, Tarallo M (2016) A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective. Rheumatol Int 36(5):685\u2013695. https:\/\/doi.org\/10.1007\/s00296-015-3415-x","journal-title":"Rheumatol Int"},{"issue":"10","key":"7700_CR8","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/nrrheum.2009.181","volume":"5","author":"PC Taylor","year":"2009","unstructured":"Taylor PC, Feldman (2009) Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat Rev Rheumatol 5(10):578\u201382. https:\/\/doi.org\/10.1038\/nrrheum.2009.181","journal-title":"Nat Rev Rheumatol"},{"key":"7700_CR9","doi-asserted-by":"publisher","first-page":"CD007848","DOI":"10.1002\/14651858.CD007848.pub2","volume":"4","author":"JA Singh","year":"2009","unstructured":"Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA et al (2009) Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev 4:CD007848. https:\/\/doi.org\/10.1002\/14651858.CD007848.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"7700_CR10","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1016\/j.clinthera.2017.06.013","volume":"39","author":"AF Wells","year":"2017","unstructured":"Wells AF, Curtis JR, Betts KA, Douglas K, Du Xiaoyan E, Ganguli A (2017) Systematic Literature Review and Meta-analysis of Tumor Necrosis Factor-Alpha Experienced Rheumatoid Arthritis. Clin Ther 39(8):1680\u20131694. https:\/\/doi.org\/10.1016\/j.clinthera.2017.06.013","journal-title":"Clin Ther"},{"issue":"6","key":"7700_CR11","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1111\/j.1524-4733.2010.00764.x","volume":"13","author":"P Li","year":"2010","unstructured":"Li P, Blum MA, von Feldt J, Hennessy S, Doshi JA (2010) Adherence, discontinuation, and switching of biologic therapies in Medicaid enrolees with rheumatoid arthritis. Value Health 13(6):805\u2013812. https:\/\/doi.org\/10.1111\/j.1524-4733.2010.00764.x","journal-title":"Value Health"},{"issue":"4","key":"7700_CR12","first-page":"14","volume":"29","author":"R Rol\u00f3nCampuzano","year":"2018","unstructured":"Rol\u00f3nCampuzano R, Dal Pra F, Schneeberger EE, Coronel Ale AL, Cerda OL, Correa MA et al (2018) Patrones de tratamiento con agentes biol\u00f3gicos. Eficacia y sobrevida a largo plazo en pacientes con artritis reumatoidea. Rev Arg Reumatol 29(4):14\u20139","journal-title":"Rev Arg Reumatol"},{"issue":"1","key":"7700_CR13","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","volume":"11","author":"JA Cramer","year":"2008","unstructured":"Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA et al (2008) Medication compliance and persistence: terminology and definitions. Value Health 11(1):44\u201347. https:\/\/doi.org\/10.1111\/j.1524-4733.2007.00213.x","journal-title":"Value Health"},{"issue":"71","key":"7700_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta21710","volume":"21","author":"A Wailoo","year":"2017","unstructured":"Wailoo A, Hock ES, Stevenson M, Martyn-St James M, Rawdin A, Simpson E et al (2017) The clinical effectiveness and cost-effectiveness of treat-to-target strategies in rheumatoid arthritis: a systematic review and cost-effectiveness analysis. Health Technol Assess 21(71):1\u2013258. https:\/\/doi.org\/10.3310\/hta21710","journal-title":"Health Technol Assess"},{"issue":"15","key":"7700_CR15","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","volume":"283","author":"DF Stroup","year":"2000","unstructured":"Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283(15):2008\u201312. https:\/\/doi.org\/10.1001\/jama.283.15.2008","journal-title":"JAMA"},{"issue":"8","key":"7700_CR16","doi-asserted-by":"publisher","first-page":"W163","DOI":"10.7326\/0003-4819-147-8-200710160-00010-w1","volume":"147","author":"JP Vandenbroucke","year":"2007","unstructured":"Vandenbroucke JP, von Elm E, Altman DG, G\u00f8tzsche PC, Mulrow CD, Pocock SJ et al (2007) Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. Ann Intern Med 147(8):W163\u2013W194","journal-title":"Ann Intern Med"},{"key":"7700_CR17","unstructured":"PROSPERO - University of York. https:\/\/www.crd.york.ac.uk"},{"issue":"7","key":"7700_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group","year":"2019","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2019) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7):e1000097. https:\/\/doi.org\/10.1371\/journal.pmed.1000097","journal-title":"PLoS Med"},{"key":"7700_CR19","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (eds) (2024) Cochrane handbook for systematic reviews of interventions version 6.5 (updated August 2024). Cochrane. Available from\u00a0https:\/\/www.cochrane.org\/handbook"},{"key":"7700_CR20","unstructured":"Higgins JPT, Green S (eds) (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from\u00a0https:\/\/www.cochrane-handbook.org.\u00a0(Chapter 8: Evaluation of risk of bias)"},{"key":"7700_CR21","unstructured":"Wells GA, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M, et al (nd) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at: https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"issue":"3","key":"7700_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i03","volume":"36","author":"W Viechtbauer","year":"2010","unstructured":"Viechtbauer W (2010) Conducting meta-analyses in R with the metaphor package. J Stat Softw 36(3):1\u201348","journal-title":"J Stat Softw"},{"key":"7700_CR23","doi-asserted-by":"publisher","first-page":"A958","DOI":"10.1136\/annrheumdis-2018-eular.2131","volume":"77","author":"M Movahedi","year":"2018","unstructured":"Movahedi M, Couta S, Cesta A, Bombardier C, on behalf of Other OBRI Investigators (2018) Time to discontinuation of biologic therapy by mechanism of action in rheumatoid arthritis: results from the Ontario best practice research initiative (OBRI) cohort. Ann Rheum Dis 77:A958","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"7700_CR24","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s13075-019-1917-8","volume":"21","author":"D Choquette","year":"2019","unstructured":"Choquette D, Bessette L, Alemao E, Haraoui B, Postema R, Raynauld J-P et al (2019) Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata\u00ae clinical database and registry. Arthritis Res Ther 21(1):138. https:\/\/doi.org\/10.1186\/s13075-019-1917-8","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"7700_CR25","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3109\/03009742.2012.762037","volume":"42","author":"Y Hishitani","year":"2013","unstructured":"Hishitani Y, Ogata A, Shima Y, Hirano T, Ebina K, Kunugiza Y et al (2013) Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis. Scand J Rheumatol 42(4):253\u2013259. https:\/\/doi.org\/10.3109\/03009742.2012.762037","journal-title":"Scand J Rheumatol"},{"issue":"1","key":"7700_CR26","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/1756-185X.12937","volume":"21","author":"P Narongroeknawin","year":"2018","unstructured":"Narongroeknawin P, Chevaisrakul P, Kasitanon N, Kitumnuaypong T, Mahakkanukrauh A, Siripaitoon B (2018) Drug survival and reasons for discontinuation of the first biological disease modifying antirheumatic drugs in Thai patients with rheumatoid arthritis: analysis from the Thai Rheumatic Disease Prior Authorization registry. Int J Rheum Dis 21(1):170\u2013178. https:\/\/doi.org\/10.1111\/1756-185X.12937","journal-title":"Int J Rheum Dis"},{"issue":"4","key":"7700_CR27","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3899\/jrheum.181398","volume":"47","author":"P Emery","year":"2020","unstructured":"Emery P, Vlahos B, Szczypa P, Thakur M, Jones HE, Woolcott J et al (2020) Long-term drug survival of tumor necrosis factor inhibitors in patients with rheumatoid arthritis. J Rheumatol 47(4):493\u2013501. https:\/\/doi.org\/10.3899\/jrheum.181398","journal-title":"J Rheumatol"},{"key":"7700_CR28","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/764518","volume":"2013","author":"A Arora","year":"2013","unstructured":"Arora A, Mahajan A, Spuerden D, Boyd H, Porter D (2013) Long-term drug survival of TNF inhibitor therapy in RA patients: a systematic review of European national drug registries. Int J Rheumatol 2013:764518. https:\/\/doi.org\/10.1155\/2013\/764518","journal-title":"Int J Rheumatol"},{"key":"7700_CR29","unstructured":"Choquette D, Bessette L, Coupal L, Garces K (2017) Retention on adalimumab, etanercept, golimumab and infiximab in two eras \u2013 experience of patients with rheumatoid arthritis from a real-world database RHUMADATA\u00ae. Arthritis Rheum 69(suppl 10)"},{"issue":"2","key":"7700_CR30","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1136\/annrheumdis-2013-204128","volume":"74","author":"M Neovius","year":"2015","unstructured":"Neovius M, Arkema EV, Olsson H, Eriksson JK, Kristensen LE, Simard JF et al (2015) Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab. Ann Rheum Dis 74(2):354\u2013360. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204128","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"7700_CR31","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.jbspin.2014.02.014","volume":"81","author":"A Frazier-Mironer","year":"2014","unstructured":"Frazier-Mironer A, Dougados M, Mariette X, Cantagrel A, Deschamps V, Flipo RM et al (2014) Retention rates of adalimumab, etanercept and infliximab as first and second-line biotherapy in patients with rheumatoid arthritis in daily practice. Joint Bone Spine 81(4):352\u2013359. https:\/\/doi.org\/10.1016\/j.jbspin.2014.02.014","journal-title":"Joint Bone Spine"},{"issue":"5","key":"7700_CR32","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jbspin.2016.01.005","volume":"83","author":"B Batteux","year":"2016","unstructured":"Batteux B, Devauchelle A, Lasselin Boyard P, Sejourn\u00e9 A, Fardellone P, Go\u00ebb V (2016) Comparison of continuation rates with three TNF\u03b1 antagonists (adalimumab, infliximab, etanercept) in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: retrospective 10-year study. Joint Bone Spine 83(5):607\u2013609. https:\/\/doi.org\/10.1016\/j.jbspin.2016.01.005","journal-title":"Joint Bone Spine"},{"issue":"7","key":"7700_CR33","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1136\/annrheumdis-2011-150573","volume":"71","author":"JD Greenberg","year":"2012","unstructured":"Greenberg JD, Reed G, Decktor D, Harrold L, Furst D, Gobofsky A et al (2012) A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry. Ann Rheum Dis 71(7):1134\u20131142. https:\/\/doi.org\/10.1136\/annrheumdis-2011-150573","journal-title":"Ann Rheum Dis"},{"issue":"Suppl","key":"7700_CR34","doi-asserted-by":"publisher","first-page":"A995","DOI":"10.1136\/annrheumdis-2018-eular.1885","volume":"77","author":"B Michelsen","year":"2018","unstructured":"Michelsen B, Sexton J, Kvien TK (2018) Does biological disease-modifying anti-rheumatic drug na\u00efve versus non-na\u00cfve patients with inflammatory joint diseases have similar golimumab drug survival and efficacy? Data from the prospective observational nor-dmard study. Ann Rheum Dis 77(Suppl):A995","journal-title":"Ann Rheum Dis"},{"key":"7700_CR35","unstructured":"Grinnell M, Pedro S, Michaud K (2019) Factors influencing discontinuation in long-term RA treatment. Arthritis Rheum 71(suppl 10)"},{"issue":"3","key":"7700_CR36","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s00296-018-4177-z","volume":"39","author":"MV Hernandez","year":"2019","unstructured":"Hernandez MV, Sanchez-Piedra C, Garcia-Magallon B, Cuende E, Manero J (2019) Factors associated with long-term retention of treatment with golimumab in a real-world setting: an analysis of the Spanish BIOBADASER registry. Rheumatol Int 39(3):509\u2013515. https:\/\/doi.org\/10.1007\/s00296-018-4177-z","journal-title":"Rheumatol Int"},{"key":"7700_CR37","doi-asserted-by":"publisher","first-page":"719","DOI":"10.2147\/PPA.S128665","volume":"11","author":"A Svedbom","year":"2017","unstructured":"Svedbom A, Storck C, Kachroo S, Govoni M, Khalifa A (2017) Persistence with golimumab in immune-mediated rheumatic diseases: a systematic review of real-world evidence in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis. Patient Prefer Adherence 11:719\u2013729. https:\/\/doi.org\/10.2147\/PPA.S128665","journal-title":"Patient Prefer Adherence"},{"issue":"5","key":"7700_CR38","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-027456","volume":"9","author":"K Luttropp","year":"2019","unstructured":"Luttropp K, Dozier M, Justo N, Cornillie F, Kachroo S, Govoni M et al (2019) Real-world treatment persistence of golimumab in the management of immune-mediated rheumatic diseases in Europe: a systematic literature review. BMJ Open 9(5):e027456. https:\/\/doi.org\/10.1136\/bmjopen-2018-027456","journal-title":"BMJ Open"},{"issue":"3","key":"7700_CR39","first-page":"423","volume":"35","author":"J Calvo-Al\u00e9n","year":"2017","unstructured":"Calvo-Al\u00e9n J, Monteagudo I, Salvador G, V\u00e1zquez-Rodr\u00edguez TR, Tovar-Beltr\u00e1n JV, Vela P et al (2017) Non-adherence to subcutaneous biological medication in patients with rheumatoid arthritis: a multicentre, non-interventional study. Clin Exp Rheumatol 35(3):423\u2013430","journal-title":"Clin Exp Rheumatol"},{"issue":"9","key":"7700_CR40","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-015872","volume":"7","author":"P Bhoi","year":"2017","unstructured":"Bhoi P, Bessette L, Bell MJ, Tkaczyk C, Nantel F, Maslova K (2017) Adherence and dosing interval of subcutaneous antitumour necrosis factor biologics among patients with inflammatory arthritis: analysis from a Canadian administrative database. BMJ Open 7(9):e015872. https:\/\/doi.org\/10.1136\/bmjopen-2017-015872","journal-title":"BMJ Open"},{"issue":"6","key":"7700_CR41","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/acr.22759","volume":"68","author":"P Emery","year":"2016","unstructured":"Emery P, Fleischmann RM, Strusberg I, Durez P, Nash P, Amante EJB et al (2016) Efficacy and safety of subcutaneous golimumab in methotrexate-naive patients with rheumatoid arthritis: five-year results of a randomized clinical trial. Arthritis Care Res (Hoboken) 68(6):744\u2013752. https:\/\/doi.org\/10.1002\/acr.22759","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"7700_CR42","doi-asserted-by":"publisher","first-page":"R29","DOI":"10.1186\/ar1881","volume":"8","author":"Gomez-Reino JJ, Carmona L, BIOBADASER Group","year":"2006","unstructured":"Gomez-Reino JJ, Carmona L, BIOBADASER Group (2006) Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther 8(1):R29. https:\/\/doi.org\/10.1186\/ar1881","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"7700_CR43","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/art.22331","volume":"56","author":"Hyrich KL, Lunt M, Watson KD, Symmons DPM, Silman AJ, British Society for Rheumatology Biologics Register","year":"2007","unstructured":"Hyrich KL, Lunt M, Watson KD, Symmons DPM, Silman AJ, British Society for Rheumatology Biologics Register (2007) Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 56(1):13\u201320. https:\/\/doi.org\/10.1002\/art.22331","journal-title":"Arthritis Rheum"},{"issue":"Suppl 2","key":"7700_CR44","doi-asserted-by":"publisher","first-page":"A1159","DOI":"10.1136\/annrheumdis-2019-eular.4546","volume":"78","author":"T-H Kim","year":"2019","unstructured":"Kim T-H, Lee S-S, Park W, Song YW, Suh C-H, Kim S et al (2019) A retrospective analysis of long term safety up five years of infliximab biosimilar CT-P13 in patients with rheumatoid arthritis and ankylosing spondyloarthritis. Ann Rheum Dis 78(Suppl 2):A1159","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"7700_CR45","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1001\/jama.2016.13512","volume":"316","author":"J-E Gottenberg","year":"2016","unstructured":"Gottenberg J-E, Brocq O, Perdriger A, Lassoued S, Berthelot J-M, Wendling D et al (2016) Non-TNF-targeted biologic vs a second anti-TNF drug to treat rheumatoid arthritis in patients with insufficient response to a first anti-TNF drug. JAMA 316(11):1172\u20131180. https:\/\/doi.org\/10.1001\/jama.2016.13512","journal-title":"JAMA"},{"issue":"6","key":"7700_CR46","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1136\/annrheumdis-2011-200882","volume":"71","author":"SM Du Pan","year":"2012","unstructured":"Du Pan SM, Scherer A, Gabay C, Finckh A (2012) Differential drug retention between anti-TNF agents and alternative biological agents after inadequate response to an anti-TNF agent in rheumatoid arthritis patients. Ann Rheum Dis 71(6):997\u2013999. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200882","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"7700_CR47","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1093\/rheumatology\/keu158","volume":"53","author":"EG Favalli","year":"2014","unstructured":"Favalli EG, Biggioggero M, Marchesoni A, Meroni PL (2014) Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies. Rheumatology (Oxford) 53(9):1664\u20131668. https:\/\/doi.org\/10.1093\/rheumatology\/keu158","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"7700_CR48","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2015-000155","volume":"1","author":"S Ramiro","year":"2015","unstructured":"Ramiro S, Landew\u00e9 R, van der Heijde D, Harrison D, Collier D, Michaud K (2015) Discontinuation rates of biologics in patients with rheumatoid arthritis: are TNF inhibitors different from non-TNF inhibitors? RMD Open 1(1):e000155. https:\/\/doi.org\/10.1136\/rmdopen-2015-000155","journal-title":"RMD Open"},{"issue":"11","key":"7700_CR49","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1007\/s00228-018-2524-3","volume":"74","author":"FS Tonin","year":"2018","unstructured":"Tonin FS, Steimbach LM, Leonart LP, Ferreira VL, Borba HH, Piazza T et al (2018) Discontinuation of non-anti-TNF drugs for rheumatoid arthritis in interventional versus observational studies: a systematic review and meta-analysis. Eur J Clin Pharmacol 74(11):1513\u20131521. https:\/\/doi.org\/10.1007\/s00228-018-2524-3","journal-title":"Eur J Clin Pharmacol"},{"issue":"10","key":"7700_CR50","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.1002\/art.30463","volume":"63","author":"MC Genovese","year":"2011","unstructured":"Genovese MC, Covarrubias A, Leon G, Mysler E, Keiserman M, Valente R et al (2011) Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate. Arthritis Rheum 63(10):2854\u20132864. https:\/\/doi.org\/10.1002\/art.30463","journal-title":"Arthritis Rheum"},{"issue":"1","key":"7700_CR51","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1136\/annrheumdis-2013-203523","volume":"73","author":"GR Burmester","year":"2014","unstructured":"Burmester GR, Rubbert-Roth A, Cantagrel A, Hall S, Leszczynski P, Feldman D et al (2014) A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann Rheum Dis 73(1):69\u201374. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203523","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"7700_CR52","doi-asserted-by":"publisher","first-page":"177","DOI":"10.31138\/mjr.30.3.177","volume":"30","author":"TE Markatseli","year":"2019","unstructured":"Markatseli TE, Theodoridou A, Zakalka M, Koukli E, Triantafyllidou E, Tsalavos S et al (2019) Persistence and adherence during the first six months of Tocilizumab treatment among rheumatoid arthritis patients in routine clinical practice in Greece. Results from the single arm REMISSION II study (NCT01649817). Mediterr J Rheumatol 30(3):177\u2013185. https:\/\/doi.org\/10.31138\/mjr.30.3.177","journal-title":"Mediterr J Rheumatol"},{"issue":"3","key":"7700_CR53","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1136\/annrheumdis-2013-204577","volume":"73","author":"JL Nam","year":"2014","unstructured":"Nam JL, Ramiro S, Gaujoux-Viala C, Takase K, Leon-Garcia M, Emery P et al (2014) Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 73(3):516\u2013528. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204577","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"7700_CR54","first-page":"4","volume":"31","author":"G Citera","year":"2020","unstructured":"Citera G, Mysler E, Soriano E (2020) Treat to Persist\u201d, una profundizaci\u00f3n del \u201cTreat to Target. Rev Arg Reumatol 31(2):4\u20136","journal-title":"Rev Arg Reumatol"}],"updated-by":[{"DOI":"10.1007\/s10067-025-07839-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000}}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07700-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-025-07700-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07700-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T09:41:20Z","timestamp":1769679680000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-025-07700-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["7700"],"URL":"https:\/\/doi.org\/10.1007\/s10067-025-07700-9","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]},"assertion":[{"value":"18 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2025","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: In the original version of this article, the given and family names of all authors were incorrectly structured. The name was displayed incorrectly in all versions at the time of publication. The original article has been corrected.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":9,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":10,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s10067-025-07839-5","URL":"https:\/\/doi.org\/10.1007\/s10067-025-07839-5","order":12,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Schneeberger Emilce Edith. Speaker, advisor and\/or received grants from Abbvie, Amgen, Bristol-Myers Squibb, Johnson & Johnson, Novartis, Pfizer, Raffo, Ultragenyx.Acosta Felquer Mar\u00eda Laura. Speaker from Johnson & Johnson, Novartis.Citera Gustavo. Speaker, advisor and\/or received grants from Amgen, Abbvie, Bag\u00f3, Biosidus, Bristol-Myers Squibb, GlaxoSmithKline, Johnson & Johnson, Novartis, Pfizer, Raffo.Soriano Enrique. Speaker, advisor and\/or received grants from Abbvie, Amgen, Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson, Novartis, Pfizer, Roche, UCB.Mysler Eduardo. Speaker, advisor and\/or received grants from Abbvie, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Hi Bio, Johnson & Johnson, Merck, Pfizer, Roche, Sanofi.Masson Walter. No disclosures.Lobo Lorenzo Mart\u00edn. No disclosures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}